Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Imagabalin in Elderly Patients with Generalized Anxiety Disorder
NCT00738738Phase 3Withdrawn
- Sponsor
- Pfizer
- Start
- Jan 2009
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of imagabalin in generalized anxiety disorder (GAD), sponsored by Pfizer. Primary endpoints: Discontinuations due to adverse events or adverse events occurring during and after the discontinuation of trial medication, Suicide related adverse events assessed using the Columbia Suicide Severity Rating Scale and 2 more. Planned start Jan 2009; status: withdrawn.
02
Drugs
imagabalin
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00738738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00738738.